Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials

• Yunfang Yu,
• Yongjian Chen,
• Anlin Li,
• Qiyun Ou,
• Qingjian Li,
• Yang Gu,
• Dagui Lin,
• Wenda Zhang,
• Jingshu Wang,
• Xudong Tang,
• Zhihua Li,
• Hai Hu,
• Herui Yao

Affiliations

Yunfang Yu

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China

Yongjian Chen

Department of Medical Oncology The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

Anlin Li

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China

Qiyun Ou

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China

Qingjian Li

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China

Yang Gu

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China

Dagui Lin

State key laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China

Wenda Zhang

Guangdong Medical University Zhanjiang Guangdong China

Jingshu Wang

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China

Xudong Tang

Guangdong Medical University Zhanjiang Guangdong China

Zhihua Li

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China

Hai Hu

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China

Herui Yao

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Department of Medical Oncology Phase I Clinical Trial Centre Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong China